Description

The Securities and Exchange Commission today charged a Maryland-based biotech company and four former top executives with prioritizing revenue growth over lawful accounting and misleading investors in the process.

The SEC alleges that Osiris Therapeutics routinely overstated company performance and issued fraudulent financial statements for a period of nearly two years. According to the SECs complaint, the company improperly recognized revenue using artificially inflated prices, backdated documents to recognize revenue in earlier periods, and prematurely recognized revenue upon delivery of products to be held on consignment. Osiris Therapeutics and its executives also allegedly used pricing data that they knew was false and attempted to book revenue on a fictitious transaction, among other accounting improprieties.

As alleged in our complaint, Osiris Therapeutics falsely portrayed to investors that its revenue was growing so rapidly that its performance was consistently exceeding expectations, said Julie Lutz, Director of the SECs Denver Regional Office. Corporate cultures cannot be so fixated on higher revenues that they use illegal accounting gimmicks to meet the financial numbers they desire.

Osiris Therapeutics agreed to settle the charges without admitting or denying the allegations and must pay a $1.5 million penalty.

The litigation continues against four executives who led Osiris during the alleged period of accounting fraud from 2014 to 2015: chief executive officer Lode B. Debrabandere, chief financial officers Philip R. Jacoby Jr. and Gregory I. Law, and chief business officer Bobby Dwayne Montgomery. The SECs complaint seeks disgorgement of ill-gotten gains plus interest and penalties along with officer-and-director bars.

The SECs investigation was conducted by Laura Ordaz and Anne Romero with assistance from Judy Bizu of the Denver office. The case was supervised by Laura Metcalfe and Kurt Gottschall. The litigation will be led by Danielle Voorhees and supervised by Gregory Kasper. The SEC appreciates the cooperation of the U.S. Attorneys Office for the Southern District of New York, which filed criminal charges against Jacoby.

Comments
Order by: 
Per page:
 
  • There are no comments yet
   Comment Record a video comment
 
 
 
     
Related Feed Entries
The Securities and Exchange Commission today announced a whistleblower award of more than $2.1 million to a former company insider whose information led to multiple successful enforcement actions. The whistleblowers information strongly supported the findings in the underlying actions and the whistleblower provided ongoing assistance to the staff during the investigation. The SEC has issued nearly $90 million in whistleblower awards in the past month alone, said Jane Norberg, Chief of the SECs O…
12 days ago · From Securities Exchange Commission
The Securities and Exchange Commission today announced that three investment advisers have settled charges for breaching fiduciary duties to clients and generating millions of dollars of improper fees in the process. According to the SECs orders, PNC Investments LLC, Securities America Advisors Inc., and Geneos Wealth Management Inc. failed to disclose conflicts of interest and violated their duty to seek best execution by investing advisory clients in higher-cost mutual fund shares when lower…
06.04.2018 · From Securities Exchange Commission
The Securities and Exchange Commission has obtained a court order freezing more than $27 million in trading proceeds from allegedly illegal distributions and sales of restricted shares of Longfin Corp. stock involving the company, its CEO, and three other affiliated individuals. According to a complaint unsealed today in federal court in Manhattan, shortly after Longfin began trading on NASDAQ and announced the acquisition of a purported cryptocurrency business, its stock price rose dramatically…
06.04.2018 · From Securities Exchange Commission
The Securities and Exchange Commission today charged convicted felon and former NHL team owner Peter H. Pocklington, his medical device company, and others with defrauding investors by hiding Pocklingtons recidivist history and by misappropriating investor funds. The SEC alleges that in 2010, Pocklington pleaded guilty to a federal felony perjury charge and was later ordered to pay over $5 million as part of a settlement for unrelated state securities fraud and registration charges. Pocklingto…
05.04.2018 · From Securities Exchange Commission
The Securities and Exchange Commission today announced a whistleblower award of more than $2.2 million to a former company insider whose tips helped the agency open an investigation that led to an enforcement action. The whistleblower first reported the information to another federal agency and later provided the same information to the SEC. This is the first award paid under the safe harbor of Exchange Act Rule 21F-4(b)(7), which provides that if a whistleblower submits information to another…
05.04.2018 · From Securities Exchange Commission
Rate
0 votes
Info
Michael Blair
Time is your GREATEST asset
02.11.2017 (02.11.2017)
21 Views
0 Subscribers
Recommend